GenSight Biologics to highlight gene therapies at Cell & Gene Meeting

By The Science Advisory Board staff writers

October 11, 2021 -- French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.

Dr. Magali Taiel, the company's chief medical officer, will present virtually during a prerecorded session on developments in the pipeline for the two therapies. Lumevoq is designed to treat vision loss caused by Leber hereditary optic neuropathy, while GS030 is for retinitis pigmentosa.

Optogenetic gene therapy provides hope for retinitis pigmentosa patients
Optogenetic therapy bypasses traditional methods of repairing defective photoreceptors in the eye by targeting other retinal cells. Recently, three examples...
Diamond Pharma, GenSight submit EMA application for ocular gene therapy
French biotechnology firm GenSight Biologics has submitted a marketing authorization application to the European Medicines Agency (EMA) for its ocular...

Copyright © 2021

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter